Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons

A Naimi, RN Mohammed, A Raji, S Chupradit… - Cell communication and …, 2022 - Springer
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

S Vafaei, AO Zekiy, RA Khanamir, BA Zaman… - Cancer Cell …, 2022 - Springer
Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic
strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects …

Trial watch: STING agonists in cancer therapy

J Le Naour, L Zitvogel, L Galluzzi, E Vacchelli… - …, 2020 - Taylor & Francis
Stimulator of interferon response cGAMP interactor 1 (STING1, best known as STING) is an
endoplasmic reticulum-sessile protein that serves as a signaling hub, receiving input from …

Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis

MS Congzhou, EJ Lehrer, C Hwang, DM Trifiletti… - Radiotherapy and …, 2020 - Elsevier
Background and purpose Immune checkpoint inhibitor with radiation therapy (ICI+ RT) is
under investigation for improved patient outcome, so we performed a systematic …

Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer

R Hannan, M Christensen, H Hammers… - European urology …, 2022 - Elsevier
Background Patients with metastatic renal cell carcinoma (mRCC) treated with systemic
therapy sometimes progress at limited sites. The best treatment approach for patients with …

Stereotactic Ablative Radiation for Systemic Therapy–naïve Oligometastatic Kidney Cancer

R Hannan, M Christensen, A Christie, A Garant… - European urology …, 2022 - Elsevier
Background Evidence-based guidelines for the management of systemic therapy–naïve
oligometastatic renal cell carcinoma (RCC) are lacking. Objective To evaluate the potential …

Stereotactic ablative radiotherapy combined with immune checkpoint inhibitors reboots the immune response assisted by immunotherapy in metastatic lung cancer: a …

R Chicas-Sett, I Morales-Orue… - International journal of …, 2019 - mdpi.com
Background: Immune checkpoint inhibitors (ICI) have represented a revolution in the
treatment of non-small-cell lung cancer (NSCLC). To improve these results, combined …

The emerging role of radiation therapy in renal cell carcinoma

M Christensen, R Hannan - Cancers, 2022 - mdpi.com
Simple Summary Stereotactic ablative radiation therapy (SAbR) is a safe and effective local
therapy for renal cell cancer (RCC) with emerging and evolving indications. In this review we …

[HTML][HTML] Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?

E Sajjadi, K Venetis, C Scatena, N Fusco - Ecancermedicalscience, 2020 - ncbi.nlm.nih.gov
Precision immunotherapy is a crucial approach to improve the efficacy of anti-cancer
treatments, particularly in the metastatic setting. In this respect, accurate patient selection …

[HTML][HTML] Stereotactic ablative radiation therapy for oligoprogressive renal cell carcinoma

JE Schoenhals, O Mohamad, A Christie… - Advances in Radiation …, 2021 - Elsevier
Purpose Oligoprogression, defined as limited sites of progression on systemic therapy, in
patients with metastatic renal cell carcinoma (mRCC) is not uncommon, possibly because of …